Under construction – not a live service
Sign in
Enrolling by invitationNo phase

Comparing Receptor Markers in First and Returning Breast Cancers

Compares estrogen, progesterone and HER2 markers in first and recurrent breast cancer tumors.

Plain-language title generated from the registry record
Registry title: Comparative Expression of ER,PR and HER2/Neu in Initial and Recurrent Breast Cancer.

Key facts

Where
Sohag, EgyptSee the site

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women whose breast cancer was removed and later came back at the same site, and who had ER, PR and HER2/neu tested in both tumors.

Sex
Women only.
Disease stage
Breast cancer that was removed and then came back at the same site.
Earlier treatment
The first breast cancer must have been removed by surgery.
Biomarker or test result
ER, PR and HER2/neu must have been tested in both the first tumor and the recurrent tumor.

Main reasons for not taking part

  • Not enough clinical or pathological data
  • ER, PR or HER2/neu status missing for the first or the recurrent tumor

Read by machine on 9 November 2026.

Where in Egypt

  • Faculty of MedicineSohag, EgyptNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Sohag University
Trial code
NCT07056205
Record updated
9 July 2025
Original description
Expression of ER, PR and HER2/neu in initial and recurrent breast cancer and correlate the results to different clinical and pathological parameters as patient age,sex, tumor location, status of nodal involvement and lymphovascular invasionRead full original descriptionShow less

Comparative Expression of ER,PR and HER2/Neu in Initial and Recurrent Breast Cancer.

Expression of ER, PR and HER2/neu in initial and recurrent breast cancer and correlate the results to different clinical and pathological parameters as patient age,sex, tumor location, status of nodal involvement and lymphovascular invasion

Inclusion: Patients with excised breast cancer then experienced recurrence at same site. Patients with evaluated ER, PR and HER2/neu for both initial and recurrent tumors.

Exclusion: Cases with insufficient clinical of pathological data. Deficient ER, PR and HER2/neu status in either initial or recurrent tumor.

ClinicalTrials.gov NCT07056205